| Literature DB >> 34158874 |
Masahiro Wada1, Tomoaki Mameno1, Motohiro Otsuki1,2, Misako Kani1, Yoshitaka Tsujioka1, Kazunori Ikebe1.
Abstract
Peri-implant diseases are known as undesirable conditions that can occur after implant therapy. Although several risk indicators are becoming clear, the causes of peri-implant diseases have not been completely investigated. The purpose of this review was to summarize the prevalence and risk indicators for peri-implant diseases by referring to current papers from various angles. Many studies have reported the varied prevalence of peri-implant mucositis (23.9%-88.0% at the patient level and 9.7%-81.0% at the implant level) and peri-implantitis (8.9%-45% at the patient level and 4.8%-23.0% at the implant level). Additionally, several studies concluded that poor oral hygiene and lack of regular maintenance were strongly correlated with the development of both peri-implant mucositis and peri-implantitis. Diabetes and a history of periodontitis were revealed as risk indicators for peri-implantitis. However, there was no definitive conclusion about the correlations between peri-implant diseases and other factors such as smoking, the shape of the implant superstructure, and the condition of the keratinized mucosa. Further studies useful for evidence-based decision-making are needed for predictable implant therapy in the long term.Entities:
Keywords: Literature review; Peri-implant mucositis; Peri-implantitis
Year: 2021 PMID: 34158874 PMCID: PMC8203834 DOI: 10.1016/j.jdsr.2021.05.002
Source DB: PubMed Journal: Jpn Dent Sci Rev ISSN: 1882-7616
Studies characteristics for prevalence of peri-implant mucositis.
| Study | Study design | Number of patients/implants | Prevalence of peri-implant mucositis | Diagnostic criteria |
|---|---|---|---|---|
| Wada et al. [ | Cross-sectional mean: 5.8 years | 543/1613 | PL: 23.9% IL: 27.4% | BoP with no bone loss (≤1 mm) |
| Ogata et al. [ | Cross-sectional mean: 6.4 years | 267/267 | PL: 33.3% IL: 9.7% | BoP (<0.25 N) without changes in the level of the crestal bone |
| Marrone et al. [ | Cross-sectional mean: 8.5 years | 103/266 | PL: 31% IL: 38% | PD > 5 mm, BoP, and bone loss ≤2 mm |
| Casado et al. [ | Cross-sectional range: 1–5 years | 103 | PL: 19.4% | BoP, red mucosa, and swelling with no bone loss (no described criteria) |
| Máximo et al. [ | Cross-sectional mean: 3.4 years | 113/347 | PL: 36.3% IL: 32.0% | BoP and bone loss <3 threads |
| Ferreira et al. [ | Cross-sectional mean: 3.5 years | 212/578 | PL: 64.6% IL: 62.6% | BoP with no bone loss (no described criteria) |
PL; patient level, IL; implant level.
Studies characteristics for prevalence of peri-implantitis.
| Study | Study design | Number of patients/implants | Prevalence of peri-implantitis | Diagnostic criteria |
|---|---|---|---|---|
| Renvert et al. [ | Cohort 20−26 years | 86/351 | PL: 15.1% at 9−14 years follow-up IL: 4.8% at 9−14 years follow-up 10.8% at 20−26 years follow-up | ≥3 threads exposed, and BoP/Sup |
| Wada et al. [ | Cross-sectional mean: 5.8 years | 543/1613 | PL: 15.8% IL: 9.2% | BoP/Sup and bone loss >1 mm after 1 year of function |
| Derks et al. [ | Cross-sectional mean: 8.9 years | 427/1578 | PL: 45.0 % (moderate/severe: 14.5%) IL: 24.9% (moderate/severe: 8.0%) | BoP/Sup and bone loss >0.5 mm (moderate/severe: BoP/Sup and bone loss >2 mm) |
| Aguirre-Zorzano et al. [ | Cross-sectional mean: 5.3 years | 239/786 | PL: 15.1% IL: 9.8% | BoP and bone loss>1.5 mm |
| Dalago et al. [ | Cross-sectional mean: 5.6 years | 183/938 | PL: 16.4% IL: 7.3% | PD > 5 mm, BoP/Sup, and bone loss>2 mm |
| Rokn et al. [ | Cross-sectional mean: 4.4 years | 134/478 | PL: 20.1% IL: 8.8% | BoP/Sup and bone loss>2 mm |
| Schwarz et al. [ | Cross-sectional mean: 2.2 years | 238/512 | PL: 13.9% IL: 7.6% | BoP/Sup and bone loss compared to baseline |
| French et al. [ | Cohort 5−10 years | 2060/4591 | PL: 11.7% (strict), 7.8% (relaxed) IL: 7.7% (strict), 5.9% (relaxed) | strict: single-point BoP and bone loss≥1.0 mm at least 1 year after installation relaxed: multi-point BoP and bone loss≥1.0 mm at least 1 year after installation |
PL; patient level, IL; implant level.